

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5967801

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARCEL BONN-MILLER	09/30/2018
NANCY TICH	09/26/2018
DONNA GUTTERMAN	09/25/2018
JOHN MESSENHEIMER	09/25/2018
TERRI SEBREE	09/26/2018
RECEIVING PARTY DATA	
Name:	ZYNERBA PHARMACEUTICALS, INC.
Street Address:	80 W. LANCASTER AVENUE
Internal Address:	SUITE 300
City:	DEVON
State/Country:	PENNSYLVANIA
Postal Code:	19333
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16594317
CORRESPONDENCE DATA	
Fax Number:	(857)302-6843
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	857 287-3100
Email:	Maureen.Tierney@wbd-us.com
Correspondent Name:	WOMBLE BOND DICKINSON (US) LLP
Address Line 1:	INDEPENDENCE WHARF
Address Line 2:	470 ATLANTIC AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	Z103015 1140US.C4
NAME OF SUBMITTER:	MAUREEN TIERNEY
SIGNATURE:	/Maureen Tierney/
DATE SIGNED:	02/18/2020

Total Attachments: 7

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page1.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page2.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page3.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page4.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page5.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page6.tif

source=FXS Assignment (Executed by all inventors) Z103015 1140US#page7.tif

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each undersigned inventor (hereinafter referred to singly and collectively as "ASSIGNOR") has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto

Zynerba Pharmaceuticals, Inc.
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333

(hereinafter referred to as "ASSIGNEE") its successors and assigns, the full and exclusive right, title and interest for the United States, its territories and possessions, and all foreign countries in and to this invention relating to

TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL

the application having been executed on even date herewith, and/or as set forth in the following Patent Applications:

United States Utility Application No.	16/144,632	, filed	9/27/2018
	PCT/IB2018/058519		9/27/2018
International Patent Application No.		, filed	

as well as in and to (a) all improvements and modifications of the above-identified invention or inventions, (b) the above-identified applications and all other applications for Letters Patent of the United States and countries foreign thereto for above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES ASSIGNEE to file patent applications in any or all countries on the above-identified invention or inventions in the name of the undersigned or in the name of ASSIGNEE or otherwise as ASSIGNEE may deem advisable under the International Convention or otherwise.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representative or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, and declarations, depositions; and (d) to provide all reasonable assistance to ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **Womble Bond Dickinson (US) LLP** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **Womble Bond Dickinson (US) LLP** do not personally represent ASSIGNOR OR ASSIGNORS' legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.


Executed this 25th day of September, 2018.

9/25/18
Date


Donna Gutterman

Witness:

9/25/18
Date


Name: Suzanne M. Horton

Executed this _____ day of _____, 2018.

Date

John Messenheimer

Witness:

Date

Name:

Executed this 30th day of September, 2018.

09/30/2018

Date



Marcel Bonn Miller

Witness:

09/30/2018

Date



Name: Jessica G. Irons

Executed this _____ day of _____, 2018.

Date

Donna Gutterman

Witness:

Date

Name:

Executed this 25th day of September, 2018.

Date

9/25/18

John Messenheimer

John Messenheimer

Witness:

Date

9/25/18

Name:

Carla Ball

Executed this 26th day of September 2018.

26 Sept 2018
Date

Terri Sebree
Terri Sebree

Witness:

26 - Sept - 2018
Date

Deanne M. Henton
Name: Deanne M. Henton

Executed this _____ day of _____, 2018.

Date

Marcell Bonn Miller


Witness:

Date

Name:

Executed this 26 day of September, 2018.

26 - Sept. - 2018
Date


Nancy Tich

Witness:

26 - Sept - 2018
Date


Name: SUZANNE M. HEDLON